Merck Highlighted 5 Year Results from the P-II OLE Trial of Evobrutinib for Relapsing Multiple Sclerosis
Shots:
- The P-II OLE trial evaluating evobrutinib which showed sustained clinical efficacy & safety with no evidence of clinical worsening in 87.1% of patients in 5yr.
- Patients were switched from evobrutinib (75mg, qd) to 75mg, BID resulting in additional ARR reduction & no new safety signals were seen. The therapy continued to show consistent tolerability up to 5yr. of treatment & the results indicate sustained benefit of long-term BID dosing
- The safety profile was consistent with prior reported studies over 5yrs. of therapy. Additional results showed improvements in mental health & QoL measures, results presented at the 9th Joint ECTRIMS-ACTRIMS meeting indicate the long-term positive benefits of evobrutinib
Ref: Merck | Image: Merck
Related News:- Merck Reports P-III Trial (KEYNOTE-671) Results of Keytruda for Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
